Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.
about
Therapeutic Implications of Targeting AKT Signaling in MelanomaThe proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in miceIncreased expression of a proline-rich Akt substrate (PRAS40) in human copper/zinc-superoxide dismutase transgenic rats protects motor neurons from death after spinal cord injuryInsulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40Current phase II clinical data for ridaforolimus in cancer.PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells.Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interaction.Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignanciesPRAS40: target or modulator of mTORC1 signalling and insulin action?The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.Role of PRAS40 in Akt and mTOR signaling in health and disease.Mammalian target of rapamycin and the kidney. I. The signaling pathway.Proteomic profile of maternal-aged blastocoel fluid suggests a novel role for ubiquitin system in blastocyst quality.PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy.Overexpression of Na+/Mg2+ exchanger SLC41A1 attenuates pro-survival signaling.PRAS40 Connects Microenvironmental Stress Signaling to Exosome-Mediated Secretion.Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases
P2860
Q24631438-33ABAEF9-1BFB-4647-93FC-8782476D3088Q24634783-5B22C368-9B01-477E-8188-384B0E071431Q24658113-A170FC70-3863-4131-B3D3-815D4D87A7D4Q28575854-60BE6F39-B81B-4CE5-A74D-14C8903B94D5Q29617097-97EB7532-67E5-4A65-97ED-2C5247EB4FCDQ30662689-7ED2C776-7588-45E2-9A17-24274D5FC3D5Q33306700-09CDCA33-EA65-43FA-A8AD-7A72780D1848Q35705897-74D94BFF-0BD5-4574-99B8-902C8ACBD8E3Q36009300-C69D6B65-9465-4B20-9A63-0E25A4F9B73DQ36852932-C31C8BD9-DB82-4DEF-8577-86A8E16C8611Q37195644-E75CDDD0-63EF-440A-B14A-55950EA018C9Q37500523-5511F4EA-CDE3-4082-ACCD-4753395D4D3BQ37506648-52F7717A-25A2-4871-9247-C22E9AAD8F56Q37987085-4040A9AB-9B9A-486F-BD64-56BF144A79FCQ37993823-C35C9582-7250-4189-814E-E22457209372Q39125376-792A1BFF-A74E-4A6F-BB21-74BC708E4CADQ42713697-E8C7434F-FD39-4D29-87C1-4A675A1DE8EBQ49627161-571EF60E-F16C-4DF4-97CA-9071C55FA709Q50909332-4C9A2801-48F1-4EA3-96D5-19B3A5ED297CQ57300947-0DB9ADE0-40A1-4C53-A930-6B3EA63ABC14
P2860
Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@ast
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@en
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@nl
type
label
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@ast
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@en
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@nl
prefLabel
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@ast
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@en
Expression of proline-rich Akt ...... al pathway and carcinogenesis.
@nl
P2860
P1476
Expression of proline-rich Akt ...... val pathway and carcinogenesis
@en
P2093
P2860
P304
P356
10.1111/J.1745-7254.2005.00184.X
P50
P577
2005-10-01T00:00:00Z
P5875
P6179
1041166473